Major Study Debunks Link Between Tylenol Use in Pregnancy and Autism A large-scale study published in JAMA Pediatrics and supported by sibling analysis from Sweden has found no evidence that acetaminophen (Tylenol) use during pregnancy causes autism, challenging prior unsubstantiated claims. A comprehensive study published in JAMA Pediatrics has definitively demonstrated that the use of acetaminophen, commonly known by the brand name Tylenol, during pregnancy does not increase the likelihood of children developing autism. This significant research analyzed data from an extensive cohort of 1.5 million children born between 1997 and 2022, providing a robust statistical foundation for its conclusions. The findings revealed that approximately 1.8% of children whose mothers took acetaminophen during gestation were later diagnosed with autism, a figure that is not statistically different from the 3.0% of children who did not experience such exposure. Further reinforcing these conclusions, a separate study originating from Sweden employed a sibling analysis, a method designed to control for genetic and familial environmental factors. This approach also found no causal relationship between prenatal acetaminophen exposure and the development of autism. The scientific consensus increasingly points towards a complex interplay of genetic predispositions and environmental influences as the primary drivers of autism spectrum disorder. Crucially, neither acetaminophen nor vaccines have been identified as causal agents in its development. This new body of evidence directly contradicts previous unsubstantiated claims made by the Trump administration, which had urged pregnant mothers to avoid Tylenol without presenting any scientific evidence to support these recommendations. In September, during a press event at the White House, former President Donald Trump stated, With Tylenol, don't take it. Don't take it. If you can't live, if your fever is so bad, you have to take one, because there's no alternative to that. Following these pronouncements, the Food and Drug Administration (FDA) initiated a review process to potentially update the safety labeling for acetaminophen, suggesting a link between its use during pregnancy and autism. This potential regulatory shift prompted an immediate response from Kenvue, the manufacturer of Tylenol. In a statement, Kenvue asserted, We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers. They emphasized that Tylenol is often one of the few safe and available options for pregnant women to manage pain and fever, conditions that, if left untreated, can themselves pose significant health risks to both the mother and the developing fetus. The use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil) is generally not recommended during pregnancy due to potential complications. The impact of the administration's prior statements was evident, with reports indicating a 16% drop in Tylenol usage in emergency departments in the immediate aftermath of the announcement. ABC News sought comment from Kenvue for an update but had not received a response at the time of reporting